Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation

---
identifier: "/us/fr/2019-14887"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2019-14887"
section_name: "Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation"
positive_law: false
currency: "2019-07-12"
last_updated: "2019-07-12"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2019-14887"
document_type: "notice"
publication_date: "2019-07-12"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "84 FR 33267"
fr_volume: 84
docket_ids:
  - "Docket No. FDA-2019-N-1346"
fr_action: "Notice."
---


#  Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients; Public Workshop; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration is announcing the cancellation of a public workshop entitled “Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients” that was previously scheduled for August 8, 2019, from 8:30 a.m. to 4:30 p.m. This public workshop was announced in the *Federal Register* of May 2, 2019. The meeting has been cancelled due to unforeseen changes in the adenovirus drug development landscape.

**FOR FURTHER INFORMATION CONTACT:**

Lori Benner and/or Jessica Barnes, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300, about this public workshop, which was announced in the *Federal Register* of May 2, 2019 (84 FR 18848).

Dated: July 8, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.